



January 5, 2026

To
The Manager – Listing Compliance
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400001

Scrip Code: 524632

Dear Sir / Madam,

Sub.: Intimation for Corporate Announcement under Regulation 30 of SEBI (LODR)
Regulations pertaining to MOU with , Borns Medical Robotics Inc., USA

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Shukra Pharmaceuticals Limited ("the Company") has entered into a Memorandum of Understanding ("MOU") and received on January 05, 2026, with Borns Medical Robotics Inc., USA, a globally recognized company in robotic surgical technologies.

1. Brief Details of the MOU

The MOU sets out the framework for collaboration between the parties to introduce, promote and commercialize next-generation AI-enabled soft-tissue surgical robotic systems across India and select South Asian markets, including Nepal, Bangladesh, Sri Lanka, Maldives and Bhutan, subject to applicable regulatory approvals. The entire work will be executed through Shukra Robotics Pvt. Ltd., a subsidiary of M/s. Shukra Pharmaceuticals Ltd.

2. Strategic Rationale and Scope

Under the proposed collaboration, the parties intend to focus on:

- (a) Expanding access to advanced robot-assisted minimally invasive soft-tissue surgeries by leveraging high-precision and stability-driven robotic platforms.
- (b) Integration of artificial intelligence and digital surgery workflows to enable standardized procedure pathways and enhanced clinical efficiency.
- (c) Strengthening regional healthcare infrastructure through technology transfer, clinician training, and scalable deployment models.
- (d) Borns Medical Robotics Inc. will contribute its expertise in surgical robotics platforms and AI-enabled technologies, while the Company will leverage its established presence, regulatory execution capabilities, and healthcare market reach in India and South Asia.

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

This strategic collaboration aligns with the Company's long-term growth strategy of diversifying into high-value, technology-driven healthcare segments. The proposed association is expected to:

- (a) Enhance the Company's consolidate business portfolio and market positioning in advanced medical technologies.
- (b) Create new revenue opportunities through commercialization, partnerships with hospitals, and ecosystem development.
- (c) Strengthen the Company's brand visibility and competitive advantage in emerging digital healthcare solutions.
- (d) Support sustainable long-term value creation for shareholders by participating in a rapidly growing global surgical robotics market.

The MOU is non-binding in nature and outlines the intent of the parties to explore definitive agreements in due course, subject to detailed commercial terms, regulatory approvals, and mutual consent.

We request you to kindly take the above information on record.

Thanking you,

Yours faithfully,

For Shukra Pharmaceuticals Limited

Dakshesh Shah
Managing Director
DIN: 00561666



Encl - as above

CIN : L24231GJ1993PLC019079



Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Pursuant to SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024)

Sr. No.	Particulars	Details
1	Name(s) of parties to the agreement	Shukra Pharmaceuticals Limited and Borns Medical Robotics Inc., USA, through Shukra Robotics Pvt. Ltd. (Subsidiary of Shukra Pharmaceuticals Ltd.)
2	Purpose of entering into the agreement	To explore collaboration for introduction, promotion and commercialization of AI-enabled soft-tissue surgical robotic systems in India and select South Asian markets
3	Size of agreement	Not applicable at this stage, as the MOU is non-binding and does not specify any monetary consideration
4	Shareholding, if any, in the entity with whom the agreement is executed	Not applicable; there is no equity participation or shareholding arrangement
5	Significant terms of the agreement (in brief)	The MOU outlines a framework for collaboration to introduce and commercialize next-generation AI-enabled surgical robotic systems, subject to regulatory approvals and execution of definitive agreements. The entire work will be executed through Shukra Robotics Pvt. Ltd., a subsidiary of M/s. Shukra Pharmaceuticals Ltd.
6	Whether the transaction would fall within related party transactions?	No
7	Whether the transaction is done at arm's length	Yes
8	In case of issuance of shares to the parties, details thereof	Not applicable
9	Any other disclosures related to such agreements	The MOU is non-binding in nature and does not create any legally enforceable obligations. Definitive agreements, if any, shall be executed in future subject to mutual consent, commercial terms and regulatory approvals

CIN : L24231GJ1993PLC019079